Article
False-Positive Circulating Tumor DNA Results Do Not Explain Lack of Efficacy for PARP Inhibitors in Patients With Castration-Resistant Prostate Cancer Harboring ATM and CHEK2 Mutations.
JCO precision oncology - 1 Aug 2024
Fallah Jaleh, Xu Jianjin, Joeng Hee-Koung, Weinstock Chana, Heiss Brian L, Maguire William F, Gao Xin, Cheng Joyce, Chang Elaine, Agrawal Sundeep, Fiero Mallorie H, Pazdur Richard, Kluetz Paul G, Amiri-Kordestani Laleh, Suzman Daniel L
Abstract excerpt
False-positive ctDNA results do not explain lack of efficacy for PARPi in patients with ATMm and CHEK2m CRPC.
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.